Figure 7

Icaritin induces EBV lytic-phase gene expression and sensitizes ENKL cells to GCV treatment. A-a (B-a). ENKL cells were treated with Icaritin at indicated concentrations for 48 h and the mRNA levels of EBV-encoded genes (BZLF1, BRLF1, BMRF1, and EBNA1) were determined by Real-Time PCR (n = 3). *p < 0.05, ^#p < 0.01 vs control. A-b (B-b). SNK-10 cells (SNT-8 cells) were treated with 50 μM (32 μM) Icaritin or DMSO for indicated time and the mRNA levels of EBV-encoded genes (BZLF1, BRLF1, BMRF1, and EBNA1) were determined by Real-Time PCR (n =3). *p < 0.05, ^#p < 0.01 vs control. A-c (B-c). SNK-10 cells (SNT-8 cells) were treated with Icaritin at indicated concentrations for 48 h and the protein level of the IE protein Zta was determined by western blot analysis. A-d (B-d). Icaritin sensitizes ENKL cells to GCV treatment. SNK-10 and SNT-8 cells were treated respectively with Icaritin, GCV, or both for 48 h and the cell apoptosis was determined by flow cytometry with annexin V-FITC/PI double-staining (n = 3). ^#p < 0.01.